Coeptis Therapeutics Inc (OTCMKTS: COEP) and Statera Biopharma Inc (NASDAQ: STAB) have announced a strategic deal. The agreement allows Coeptis to purchase Statera’s TLR5 agonist technology platform. Entolimod is a product included in the acquisition. The therapy is for treating acute radiation syndrome.
Terms of the arrangement
As per the agreement, Coeptis will pay $6 million to Statera. The latter will also be entitled to milestone payments decided upon in their definitive agreement. This transaction will be made for other assets, such as the right by Statera to products with entolimod and TLR5 agonists consists similar to it. It will also include data and inventory related to TLR5 products, contract rights and intellectual property.
Entolimod is significantly advanced compared to other TLR5 agonist receptors Statera has developed. The company is currently testing it as a potential therapy for acute radiation syndrome. Moreover, Statera has found that the TLR5 agonist can treat anaemia and neutropenia in patients with cancer.
According to Coeptis Therapeutics’ CEO and President, Dave Mehalick, the company can leverage the TLR5 platform that Statera developed to treat various diseases with high unmet needs.
The threat of nuclear war makes the drug important
Mehalick adds that the company is excited to improve entolimod and apply it to treat acute radiation syndrome. This drug is essential in the existing geopolitical environment. With the threat of nuclear war being stronger than ever, the company hopes to find an efficient way to treat radiation exposure without using different medications. Furthermore, the treatment could help the company improve the anaemia and neutropenia victims
Coeptis Therapeutics, which is a subsidiary of Coeptis Pharmaceuticals, develops cancer therapy platforms that are highly innovative and can significantly improve the lives of patients. The company’s product portfolio has several drugs, such as CD38-Diagnostic and CD38- GEAR-NK. The latter is a natural killer therapeutic that the company creates from a patient’s cells. The compound undergoes gene editing to allow the researchers to combine it with anti CD38 monoclonal antibodies.
CD3undergonestic, on the other hand, enables the team to evaluate the patients that could benefit the most from CD38 monoclonal antibody therapy either alone or when used with CD38-GEAR-NK.
